The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients with related rare genetic disorders, Bloomberg’s Gerry Smith reports. This shift aims to accelerate one-time, potentially curative treatments for very small patient populations and encourage industry investment. The move reflects the agency’s effort to adapt regulation to rapid scientific advances like CRISPR. Publicly traded stocks in the sector include Crispr Therapeutics (CRSP) and Editas Medicine (EDIT).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Video: This stock is dragging down the in vivo gene editing therapy space
- Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Intellia Therapeutics price target lowered to $30 from $36 at BofA
- Editas Medicine management to meet with Cantor